302 related articles for article (PubMed ID: 28665313)
1. Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.
Uldry E; Faes S; Demartines N; Dormond O
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28665313
[TBL] [Abstract][Full Text] [Related]
2. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
3. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
4. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
Maes H; Olmeda D; Soengas MS; Agostinis P
FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
Fabian KL; Storkus WJ
Adv Exp Med Biol; 2017; 1036():191-211. PubMed ID: 29275473
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of tumor endothelial cells and drug delivery.
Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation.
Collet G; Skrzypek K; Grillon C; Matejuk A; El Hafni-Rahbi B; Lamerant-Fayel N; Kieda C
Vascul Pharmacol; 2012; 56(5-6):252-61. PubMed ID: 22446152
[TBL] [Abstract][Full Text] [Related]
8. Vaccination approach to anti-angiogenic treatment of cancer.
Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
[TBL] [Abstract][Full Text] [Related]
9. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.
Dutour A; Rigaud M
Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
11. Tumour-Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis.
Lopes-Bastos BM; Jiang WG; Cai J
Anticancer Res; 2016 Mar; 36(3):1119-26. PubMed ID: 26977007
[TBL] [Abstract][Full Text] [Related]
12. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
13. The dark side of tumor-associated endothelial cells.
De Sanctis F; Ugel S; Facciponte J; Facciabene A
Semin Immunol; 2018 Feb; 35():35-47. PubMed ID: 29490888
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
15. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.
Molema G; de Leij LF; Meijer DK
Pharm Res; 1997 Jan; 14(1):2-10. PubMed ID: 9034214
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
17. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
18. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy.
Kidoya H; Kunii N; Naito H; Muramatsu F; Okamoto Y; Nakayama T; Takakura N
Oncogene; 2012 Jul; 31(27):3254-64. PubMed ID: 22037214
[TBL] [Abstract][Full Text] [Related]
19. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.
Wroblewski M; Bauer R; Cubas Córdova M; Udonta F; Ben-Batalla I; Legler K; Hauser C; Egberts J; Janning M; Velthaus J; Schulze C; Pantel K; Bokemeyer C; Loges S
Nat Commun; 2017 Aug; 8(1):269. PubMed ID: 28814715
[TBL] [Abstract][Full Text] [Related]
20. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
